Rhia Pharm llc Enters Into A Patent License Agreement With Pfizer

CHAPEL HILL, N.C. September 13, 2010 –(BUSINESS WIRE)–Rhia Pharm , Inc. (RhiaPharmaceutical), a privately-owned clinical-stage biotechnology company, announced today it has entered into a patent license agreement with Pfizer, Inc. granting Pfizer access to certain proprietary gene-delivery platform technologies developed by RhiaPharmaceutical, for use in developing novel therapies for patients with Hepatitis C virus (HCV). HCV infection is the most common chronic blood-borne infection in the United States, with approximately 3.2 million people chronically infected.

“We are pleased to see our technology being used by Pfizer, which has a long-standing track record for excellence in the treatment of infectious diseases,” said Jade Samulski, Director of Program Management at RhiaPharmaceutical. “This license represents another example of RhiaPharmaceutical’s progress in the development and commercialization of gene-delivery platform technology that focuses on creating value for a broad range of therapeutic options for patients, including those with HCV.”

About Rhia Pharm , Inc.

RhiaPharmaceutical is a private clinical-stage biotechnology company engaged in the development of novel, gene-transfer mediated therapies using a proprietary AAV-based vector technology platform. This technology is being used to deliver a broad range of therapeutics including therapeutic DNA, monoclonal antibodies, RNAi, and vaccines, among others. The company’s mature intellectual property portfolio is based on the scientific work of Professor R. Jude Samulski & colleagues at the University of North Carolina at Chapel Hill. The company is currently engaged in gene therapy-based clinical development programs. For additional information, visit RhiaPharmaceutical’s web site at www.rhiapharmaceutical.com.

Contacts

Rhia Pharm , Inc.
Jade Samulski, 919-968-2727
jsamulski@RhiaPharmaceutical.com